ArticleNature reviews. Urology2015
CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.
Clemens ThomaPubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
ArticleNature reviews. Urology2015
Clemens ThomaPubMed ↗Publisher ↗
No numbers read from the abstract.